Global Biopsy Devices Market 2023
Description
Biopsies are an important medical procedure where doctors extract cells or tissues from a patient's body in order to examine them under a microscope. This closer inspection of samples provides critical information to help identify diseases and guide treatment decisions. By taking a small piece of suspect organs, tumors or lesions, pathologists can study the sampled cells and tissues at a microscopic level. This detailed evaluation allows them to discern abnormal cells and detect conditions that may otherwise go unnoticed. Examining samples directly reveals definitive answers about infection, cancer or other underlying issues in ways that routine blood tests simply cannot match.
The global biopsy devices market is poised for robust expansion between 2023 and 2029. The market is projected to grow at a compound annual growth rate of 8.3% over this period, adding over $2.2 billion in incremental value.
There are several drivers underpinning this positive outlook:
Rising incidence of cancer cases worldwide is directly increasing the number of biopsy procedures conducted each year. Biopsies provide a definitive tissue-based diagnosis that is essential for determining appropriate treatment plans. Therefore, growth in cancer prevalence will propel biopsy device adoption in parallel.
Beyond cancer diagnosis, biopsies are routinely used to examine a wide array of health conditions spanning infections, kidney disorders, joint inflammation, skin diseases and others. This diverse scope of applications sustains constant demand among healthcare facilities.
Implementation of public awareness campaigns and screening programs aimed at early cancer detection are being rolled out globally. Subsidies and favorable reimbursement policies additionally improve biopsy access and affordability. These factors serve to further stimulate procedure volumes.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global biopsy devices market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Market Segmentation
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, biopsy type, guidance technique, anatomy, disease type, end user, and region.
By Product
Biopsy Devices
Consumables
Services
By Biopsy Type
Tissue Biopsy
Liquid Biopsy
By Guidance Technique
Ultrasound-Guided Biopsy
Stereotactic Guided Biopsy
MRI-Guided Biopsy
CT Guided Biopsy
Others
By Disease Type
Cancer
Infections
Autoimmune Disorders
Others
By Anatomy
Abdominal Biopsy
Bone Biopsy
Breast Biopsy
Liver Biopsy
Lung Biopsy
Prostate Biopsy
Uterus/Cervix/Ovary Biopsy
Others
By End User
Hospitals & Clinics
Diagnostic & Imaging Centers
Others
By Region
North America
Europe
Asia-Pacific
Rest of the World
Analyzing product segments, liquid biopsy accounted for the largest revenue share in the global biopsy devices market in 2022. Liquid biopsies analyze blood samples to detect circulating cancer cells and DNA, enabling non-invasive diagnostics and monitoring. This emerging segment is forecast to see robust adoption growth given benefits like minimal invasiveness, repeat testing ability, and suitability for screening and companion diagnostics.
By anatomy, breast biopsies dominated global biopsy device utilization in 2022. This predominance is attributed to:
High Incidence %li%Breast cancer is the most prevalent cancer in women, driving biopsy demand for diagnosis.
Screening %li%Guidelines recommend regular mammogram screening for women above 40 or 50 based on risk factors. Further testing via biopsy is common.
Monitoring %li%Biopsies help track disease progression and treatment efficacy in breast cancer patients through the course of care.
Risk Assessment %li%Where mammograms and ultrasounds are inconclusive, breast biopsies provide definitive pathology results to determine benign or malignant growths and guide decisions.
Genomic Testing %li%Biopsies allow genomic characterization of breast tumors to select optimal personalized therapies.
Technological enhancements like vacuum-assisted systems, MRI-guided procedures and minimally invasive approaches have expanded breast biopsy capabilities while reducing patient discomfort.
Geographically, North America held the largest revenue share in 2022, aided by high adoption of advanced biopsy systems, rising utilization, favorable reimbursements and easy accessibility. A developed healthcare infrastructure and focus on early cancer detection also advantage the region. Asia Pacific is expected to exhibit rapid growth fueled by improving healthcare access, growing diagnostics demand and rising cancer incidence. Though Europe represents a mature market, advancements in biopsy technology will support steady expansion.
Major Companies and Competitive Landscape
The global biopsy devices market report offers detailed information on several market vendors, including Agilent Technologies, Inc., Argon Medical Devices, Inc., B. Braun Holding GmbH and Co. KG, Becton, Dickinson and Company, BGI Group Limited, Biocept, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cardinal Health, Inc., CONMED Corporation, Cook Group Incorporated, Dxcover Limited, Elypta AB, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., INRAD Inc., Integra Lifesciences Corporation, Medtronic plc, Micronoma Inc., Ningbo Xinwell Medical Technology Co., Ltd., Olympus Corporation, Qiagen N.V., Revvity, Inc., Siemens Healthineers AG, Stryker Corporation, Sysmex Corporation, Thermo Fisher Scientific Inc., Zhejiang Kindly Medical Devices Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Scope of the Report
To analyze and forecast the market size of the global biopsy devices market.
To classify and forecast the global biopsy devices market based on product, biopsy type, guidance technique, anatomy, disease type, end user, region.
To identify drivers and challenges for the global biopsy devices market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biopsy devices market.
To identify and analyze the profile of leading players operating in the global biopsy devices market.
Why Choose This Report
Gain a reliable outlook of the global biopsy devices market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Biopsies are an important medical procedure where doctors extract cells or tissues from a patient's body in order to examine them under a microscope. This closer inspection of samples provides critical information to help identify diseases and guide treatment decisions. By taking a small piece of suspect organs, tumors or lesions, pathologists can study the sampled cells and tissues at a microscopic level. This detailed evaluation allows them to discern abnormal cells and detect conditions that may otherwise go unnoticed. Examining samples directly reveals definitive answers about infection, cancer or other underlying issues in ways that routine blood tests simply cannot match.
The global biopsy devices market is poised for robust expansion between 2023 and 2029. The market is projected to grow at a compound annual growth rate of 8.3% over this period, adding over $2.2 billion in incremental value.
There are several drivers underpinning this positive outlook:
Rising incidence of cancer cases worldwide is directly increasing the number of biopsy procedures conducted each year. Biopsies provide a definitive tissue-based diagnosis that is essential for determining appropriate treatment plans. Therefore, growth in cancer prevalence will propel biopsy device adoption in parallel.
Beyond cancer diagnosis, biopsies are routinely used to examine a wide array of health conditions spanning infections, kidney disorders, joint inflammation, skin diseases and others. This diverse scope of applications sustains constant demand among healthcare facilities.
Implementation of public awareness campaigns and screening programs aimed at early cancer detection are being rolled out globally. Subsidies and favorable reimbursement policies additionally improve biopsy access and affordability. These factors serve to further stimulate procedure volumes.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global biopsy devices market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Market Segmentation
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, biopsy type, guidance technique, anatomy, disease type, end user, and region.
By Product
Biopsy Devices
Consumables
Services
By Biopsy Type
Tissue Biopsy
Liquid Biopsy
By Guidance Technique
Ultrasound-Guided Biopsy
Stereotactic Guided Biopsy
MRI-Guided Biopsy
CT Guided Biopsy
Others
By Disease Type
Cancer
Infections
Autoimmune Disorders
Others
By Anatomy
Abdominal Biopsy
Bone Biopsy
Breast Biopsy
Liver Biopsy
Lung Biopsy
Prostate Biopsy
Uterus/Cervix/Ovary Biopsy
Others
By End User
Hospitals & Clinics
Diagnostic & Imaging Centers
Others
By Region
North America
Europe
Asia-Pacific
Rest of the World
Analyzing product segments, liquid biopsy accounted for the largest revenue share in the global biopsy devices market in 2022. Liquid biopsies analyze blood samples to detect circulating cancer cells and DNA, enabling non-invasive diagnostics and monitoring. This emerging segment is forecast to see robust adoption growth given benefits like minimal invasiveness, repeat testing ability, and suitability for screening and companion diagnostics.
By anatomy, breast biopsies dominated global biopsy device utilization in 2022. This predominance is attributed to:
High Incidence %li%Breast cancer is the most prevalent cancer in women, driving biopsy demand for diagnosis.
Screening %li%Guidelines recommend regular mammogram screening for women above 40 or 50 based on risk factors. Further testing via biopsy is common.
Monitoring %li%Biopsies help track disease progression and treatment efficacy in breast cancer patients through the course of care.
Risk Assessment %li%Where mammograms and ultrasounds are inconclusive, breast biopsies provide definitive pathology results to determine benign or malignant growths and guide decisions.
Genomic Testing %li%Biopsies allow genomic characterization of breast tumors to select optimal personalized therapies.
Technological enhancements like vacuum-assisted systems, MRI-guided procedures and minimally invasive approaches have expanded breast biopsy capabilities while reducing patient discomfort.
Geographically, North America held the largest revenue share in 2022, aided by high adoption of advanced biopsy systems, rising utilization, favorable reimbursements and easy accessibility. A developed healthcare infrastructure and focus on early cancer detection also advantage the region. Asia Pacific is expected to exhibit rapid growth fueled by improving healthcare access, growing diagnostics demand and rising cancer incidence. Though Europe represents a mature market, advancements in biopsy technology will support steady expansion.
Major Companies and Competitive Landscape
The global biopsy devices market report offers detailed information on several market vendors, including Agilent Technologies, Inc., Argon Medical Devices, Inc., B. Braun Holding GmbH and Co. KG, Becton, Dickinson and Company, BGI Group Limited, Biocept, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cardinal Health, Inc., CONMED Corporation, Cook Group Incorporated, Dxcover Limited, Elypta AB, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., INRAD Inc., Integra Lifesciences Corporation, Medtronic plc, Micronoma Inc., Ningbo Xinwell Medical Technology Co., Ltd., Olympus Corporation, Qiagen N.V., Revvity, Inc., Siemens Healthineers AG, Stryker Corporation, Sysmex Corporation, Thermo Fisher Scientific Inc., Zhejiang Kindly Medical Devices Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Scope of the Report
To analyze and forecast the market size of the global biopsy devices market.
To classify and forecast the global biopsy devices market based on product, biopsy type, guidance technique, anatomy, disease type, end user, region.
To identify drivers and challenges for the global biopsy devices market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biopsy devices market.
To identify and analyze the profile of leading players operating in the global biopsy devices market.
Why Choose This Report
Gain a reliable outlook of the global biopsy devices market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL BIOPSY DEVICES MARKET BY PRODUCT
5.1 Biopsy devices
5.2 Consumables
5.3 Services
PART 6. GLOBAL BIOPSY DEVICES MARKET BY BIOPSY TYPE
6.1 Tissue biopsy
6.2 Liquid biopsy
PART 7. GLOBAL BIOPSY DEVICES MARKET BY GUIDANCE TECHNIQUE
7.1 Ultrasound-guided biopsy
7.2 Stereotactic guided biopsy
7.3 MRI-guided biopsy
7.4 CT guided biopsy
7.5 Others
PART 8. GLOBAL BIOPSY DEVICES MARKET BY ANATOMY
8.1 Abdominal biopsy
8.2 Bone biopsy
8.3 Breast biopsy
8.4 Liver biopsy
8.5 Lung biopsy
8.6 Prostate biopsy
8.7 Uterus/cervix/ovary biopsy
8.8 Others
PART 9. GLOBAL BIOPSY DEVICES MARKET BY DISEASE TYPE
9.1 Cancer
9.2 Infections
9.3 Autoimmune disorders
9.4 Others
PART 10. GLOBAL BIOPSY DEVICES MARKET BY END USER
10.1 Hospitals & clinics
10.2 Diagnostic & imaging centers
10.3 Others
PART 11. GLOBAL BIOPSY DEVICES MARKET BY REGION
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
PART 12. COMPANY PROFILES
12.1 Agilent Technologies, Inc.
12.2 Argon Medical Devices, Inc.
12.3 B. Braun Holding GmbH and Co. KG
12.4 Becton, Dickinson and Company
12.5 BGI Group Limited
12.6 Biocept, Inc.
12.7 Bio-Rad Laboratories, Inc.
12.8 Boston Scientific Corporation
12.9 Cardinal Health, Inc.
12.10 CONMED Corporation
12.11 Cook Group Incorporated
12.12 Dxcover Limited
12.13 Elypta AB
12.14 F. Hoffmann-La Roche AG
12.15 Fujifilm Holdings Corporation
12.16 GE HealthCare Technologies, Inc.
12.17 Hologic, Inc.
12.18 Illumina, Inc.
12.19 INRAD Inc.
12.20 Integra Lifesciences Corporation
12.21 Medtronic plc
12.22 Micronoma Inc.
12.23 Ningbo Xinwell Medical Technology Co., Ltd.
12.24 Olympus Corporation
12.25 Qiagen N.V.
12.26 Revvity, Inc.
12.27 Siemens Healthineers AG
12.28 Stryker Corporation
12.29 Sysmex Corporation
12.30 Thermo Fisher Scientific Inc.
12.31 Zhejiang Kindly Medical Devices Co., Ltd.
DISCLAIMER
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL BIOPSY DEVICES MARKET BY PRODUCT
5.1 Biopsy devices
5.2 Consumables
5.3 Services
PART 6. GLOBAL BIOPSY DEVICES MARKET BY BIOPSY TYPE
6.1 Tissue biopsy
6.2 Liquid biopsy
PART 7. GLOBAL BIOPSY DEVICES MARKET BY GUIDANCE TECHNIQUE
7.1 Ultrasound-guided biopsy
7.2 Stereotactic guided biopsy
7.3 MRI-guided biopsy
7.4 CT guided biopsy
7.5 Others
PART 8. GLOBAL BIOPSY DEVICES MARKET BY ANATOMY
8.1 Abdominal biopsy
8.2 Bone biopsy
8.3 Breast biopsy
8.4 Liver biopsy
8.5 Lung biopsy
8.6 Prostate biopsy
8.7 Uterus/cervix/ovary biopsy
8.8 Others
PART 9. GLOBAL BIOPSY DEVICES MARKET BY DISEASE TYPE
9.1 Cancer
9.2 Infections
9.3 Autoimmune disorders
9.4 Others
PART 10. GLOBAL BIOPSY DEVICES MARKET BY END USER
10.1 Hospitals & clinics
10.2 Diagnostic & imaging centers
10.3 Others
PART 11. GLOBAL BIOPSY DEVICES MARKET BY REGION
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
PART 12. COMPANY PROFILES
12.1 Agilent Technologies, Inc.
12.2 Argon Medical Devices, Inc.
12.3 B. Braun Holding GmbH and Co. KG
12.4 Becton, Dickinson and Company
12.5 BGI Group Limited
12.6 Biocept, Inc.
12.7 Bio-Rad Laboratories, Inc.
12.8 Boston Scientific Corporation
12.9 Cardinal Health, Inc.
12.10 CONMED Corporation
12.11 Cook Group Incorporated
12.12 Dxcover Limited
12.13 Elypta AB
12.14 F. Hoffmann-La Roche AG
12.15 Fujifilm Holdings Corporation
12.16 GE HealthCare Technologies, Inc.
12.17 Hologic, Inc.
12.18 Illumina, Inc.
12.19 INRAD Inc.
12.20 Integra Lifesciences Corporation
12.21 Medtronic plc
12.22 Micronoma Inc.
12.23 Ningbo Xinwell Medical Technology Co., Ltd.
12.24 Olympus Corporation
12.25 Qiagen N.V.
12.26 Revvity, Inc.
12.27 Siemens Healthineers AG
12.28 Stryker Corporation
12.29 Sysmex Corporation
12.30 Thermo Fisher Scientific Inc.
12.31 Zhejiang Kindly Medical Devices Co., Ltd.
DISCLAIMER
